MedTrace Logo

Tislelizumab Combined With Lenvatinib for Perioperative Treatment of Resectable Primary Hepatocellular Carcinoma

NCT04834986 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-04-08

No results posted yet for this study

Summary

This is a prospective, one-arm, phase II clinical study of Tislelizumab combined with Lenvatinib for perioperative treatment of resectable primary hepatocellular carcinoma with a high risk of recurrence.

Conditions

  • Resectable Hepatocellular Carcinoma

Interventions

DRUG

Tislelizumab combined with Lenvatinib

Pre-operation: Tislelizumab, 200mg, iv,d1,q3w, 2-4 cycles; Lenvatinib,8mg/kg,po,qd,d1-d84. Operation Postoperation: 4-8 weeks after surgery, Tislelizumab, 200mg, iv,d1,q3w; Lenvatinib,8mg/kg,po,qd, up to one year.

Sponsors & Collaborators

  • Tianjin Medical University Cancer Institute and Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-30
Primary Completion
2022-04-30
Completion
2024-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04834986 on ClinicalTrials.gov